摘要
目的分析达格列净与沙库巴曲缬沙坦(S/V)在糖尿病心衰患者中的临床疗效及安全性。方法选取2022年3月—2024年5月于宜兴市第五人民医院就诊的84例糖尿病心衰患者进行研究,按照红蓝摸球法将所有患者分为对照组(n=42,红)和研究组(n=42,蓝)。评估两组相关症状的发作时长[血糖达标(BGC)、心衰缓解(HFR)、乏力缓解(FR)]、血糖波动情况、心功能及不良反应。结果研究组BGC、HFR、FR用时均短于对照组(P<0.05)。治疗后,研究组空腹血糖、餐后2 h血糖水平均低于对照组(P<0.05);而E/A、LVEF、CO水平均高于对照组(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论在糖尿病心衰患者的临床治疗中,采用达格列净联合S/V的疗效显著,不仅能有效缩减患者相关症状的发作时长,还有助于调控血糖、改善心功能,且安全性良好。
Objective This study aimed to assess the effectiveness and safety of dapagliflozin combined with sacubitril valsartan(S/V)in sufferers suffering from diabetic heart failure.Methods A total of 84 diabetic heart failure sufferers admitted to Yixing Fifth People's Hospital between March 2022 and May 2024 were recruited.Employing the red-blue ball-selection method,these sufferers were allocated into a compare group(n=42,red ball,treated with S/V alone)and a investigation group(n=42,blue ball,treated with dapagliflozin in combination with S/V).The duration of related symptoms[blood glucose control(BGC),heart failure remission(HFR),fatigue remission(FR)],blood glucose variability,cardiac function parameters,and side effects were assessed between the two groups.Results The BGC,HFR,and FR of the investigation group were all shorter than compare group(P<0.05).Post-treatment,the fasting blood glucose and 2-hour post-meal blood glucose levels in the investigation group were notably lower than compare group(P<0.05).Moreover,the E/A ratio,LVEF,and CO in the investigation group were strikingly overtop than compare group(P<0.05).There was patentably indistinct in the incidence of side effects between the two groups(P>0.05).Conclusion In the clinical management of diabetic heart failure sufferers,the combination of dapagliflozin and S/V exhibits a significant curative effect.It can not only effectively shorten the onset time of related symptoms but also contribute to blood glucose regulation and cardiac function improvement,with favorable safety.
作者
钱占峰
QIAN Zhanfeng(Department of Internal Medicine,Yixing Fifth People's Hospital,Yixing,Jiangsu 214261)
出处
《智慧健康》
2025年第29期85-88,共4页
Smart Healthcare
关键词
达格列净
沙库巴曲缬沙坦
糖尿病
心衰
Dapagliflozin
Sacubitril valsartan
Diabetes
Heart failure
